38 related articles for article (PubMed ID: 19022486)
1. UroVysion
Ke C; Liu X; Wan J; Hu Z; Yang C
Front Mol Biosci; 2023; 10():1250442. PubMed ID: 37867556
[No Abstract] [Full Text] [Related]
2. The diagnostic value of fluorescence
Chen B; Shu B; Liu Z; Zhu J; Ke C; Zeng X; Hu Z; Yang C
Bladder (San Franc); 2023; 10():e21200006. PubMed ID: 37936585
[TBL] [Abstract][Full Text] [Related]
3. Technical comparison of Abbott's UroVysion
Anderson T; Hartman S; Dunn W; Bellin H; Ehlers TW; Groen S; Ramos JA
Cancer Cell Int; 2023 Dec; 23(1):314. PubMed ID: 38066541
[TBL] [Abstract][Full Text] [Related]
4. Reflex fluorescence in situ hybridization assay for suspicious urinary cytology in patients with bladder cancer with negative surveillance cystoscopy.
Kim PH; Sukhu R; Cordon BH; Sfakianos JP; Sjoberg DD; Hakimi AA; Dalbagni G; Lin O; Herr HW
BJU Int; 2014 Sep; 114(3):354-9. PubMed ID: 24128299
[TBL] [Abstract][Full Text] [Related]
5. Bladder cancer detection using FISH (UroVysion assay).
Halling KC; Kipp BR
Adv Anat Pathol; 2008 Sep; 15(5):279-86. PubMed ID: 18724101
[TBL] [Abstract][Full Text] [Related]
6. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology.
Skacel M; Fahmy M; Brainard JA; Pettay JD; Biscotti CV; Liou LS; Procop GW; Jones JS; Ulchaker J; Zippe CD; Tubbs RR
J Urol; 2003 Jun; 169(6):2101-5. PubMed ID: 12771727
[TBL] [Abstract][Full Text] [Related]
7. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings.
Yoder BJ; Skacel M; Hedgepeth R; Babineau D; Ulchaker JC; Liou LS; Brainard JA; Biscotti CV; Jones JS; Tubbs RR
Am J Clin Pathol; 2007 Feb; 127(2):295-301. PubMed ID: 17210520
[TBL] [Abstract][Full Text] [Related]
8. Quantitative molecular urinary cytology by fluorescence in situ hybridization: a tool for tailoring surveillance of patients with superficial bladder cancer?
Bollmann M; Heller H; Bánkfalvi A; Griefingholt H; Bollmann R
BJU Int; 2005 Jun; 95(9):1219-25. PubMed ID: 15892805
[TBL] [Abstract][Full Text] [Related]
9. Intermediate-risk urothelial carcinoma: an unresolved problem?
Pycha A; Lodde M; Comploj E; Negri G; Egarter-Vigl E; Vittadello F; Lusuardi L; Palermo S; Mian C
Urology; 2004 Mar; 63(3):472-5. PubMed ID: 15028440
[TBL] [Abstract][Full Text] [Related]
10. Fluorescence in situ hybridization performed on exfoliated urothelial cells in patients with transitional cell carcinoma of the bladder.
Degtyar P; Neulander E; Zirkin H; Yusim I; Douvdevani A; Mermershtain W; Kaneti J; Manor E
Urology; 2004 Feb; 63(2):398-401. PubMed ID: 14972510
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of nondiagnostic molecular changes in urine detected by UroVysion fluorescence in situ hybridization during surveillance for bladder cancer.
Nguyen CT; Litt DB; Dolar SE; Ulchaker JC; Jones JS; Brainard JA
Urology; 2009 Feb; 73(2):347-50. PubMed ID: 19022486
[TBL] [Abstract][Full Text] [Related]
12. UroVysion® multiprobe FISH in the triage of equivocal urinary cytology cases.
Bubendorf L; Piaton E
Ann Pathol; 2012 Dec; 32(6):e52-6, 438-43. PubMed ID: 23244486
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
